The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.
 
Joy X. Jarnagin
No Relationships to Disclose
 
Anurag Saraf
No Relationships to Disclose
 
Gary Chi
No Relationships to Disclose
 
Islam Baiev
No Relationships to Disclose
 
Amirkasra Mojtahed
No Relationships to Disclose
 
Jill N. Allen
No Relationships to Disclose
 
David P. Ryan
Stock and Other Ownership Interests - Acworth Pharmaceuticals; Exact Sciences; MPM Capital; Thrive Earlier Detection Corp
Honoraria - Research to Practice; UpToDate
Consulting or Advisory Role - Gritstone Bio; Innocrin Pharma; Maverick Therapeutics; MPM Capital; Oncorus; TCR2 Therapeutics; Twentyeight-Seven Therapeutics
Research Funding - Stand up to Cancer (Inst)
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; McGraw Hill Chapter Royalties
Expert Testimony - Boehringer Ingelheim
Other Relationship - TCR2 Therapeutics
 
Jeffrey William Clark
Research Funding - Pfizer (Inst)
 
Lawrence Scott Blaszkowsky
Stock and Other Ownership Interests - Pfizer (I)
 
Bruce J. Giantonio
No Relationships to Disclose
 
Colin D. Weekes
Honoraria - Bayer; Celgene; Lilly
Consulting or Advisory Role - Celgene; Ipsen; Merrimack
Research Funding - Abbvie; Actuate Therapeutics; AstraZeneca; Bayer; Celgene; Dicephera Pharmaceuticals, Inc.; Genentech/Roche; Gilead Sciences; Halozyme; Ipsen; Lilly; Millennium; Novartis
Travel, Accommodations, Expenses - Bayer; Celgene; Lilly
 
Samuel J Klempner
Stock and Other Ownership Interests - Nuvalent, Inc.; TP Therapeutics
Honoraria - Natera
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; Merck; Mersana; Pieris Pharmaceuticals; Sanofi/Aventis
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst); Silverback Therapeutics (Inst)
Other Relationship - NCCN
 
Joseph Wang Franses
Stock and Other Ownership Interests - Biogen; Merck
Consulting or Advisory Role - Foundation Medicine
Research Funding - Genentech/Roche (Inst)
 
Eric Roeland
Consulting or Advisory Role - AIM Specialty Health; Asahi Kasei; Astellas Pharma; BASF; Helsinn Therapeutics; HERON; Napo Pharmaceuticals; Oragenics; Oragenics; Pfizer/EMD Serono; Vector Oncology
Expert Testimony - Regents of the University of California
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; Exelixis; Genentech; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Nora K. Horick
Employment - Northwest Biotherapeutics (I)
Stock and Other Ownership Interests - Northwest Biotherapeutics (I)
Patents, Royalties, Other Intellectual Property - An immediate family member holds patents, has patents pending, and receives royalties from a technology relating to health or medicine. (I)
 
Ryan Bruce Corcoran
Stock and Other Ownership Interests - Avidity Biosciences; C4 Therapeutics; Erasca, Inc; Fount Therapeutics; Kinnate Biopharma; nRichDx; Remix Therapeutics; Revolution Medicines
Consulting or Advisory Role - Abbvie; Amgen; Array BioPharma; Asana Biosciences; Astex Pharmaceuticals; Avidity Nanomedicines; Bristol-Myers Squibb; C4 Therapeutics; Chugai Pharma; Elicio Therapeutics; FOGPharma; Fount Therapeutics; Genentech; Ipsen; Kinnate Biopharma; Loxo; Merrimack; N-of-One; Natera; Novartis; nRichDx; Remix Therapeutics; Revolution Medicines; Roche; Roivant; Shionogi; Shire; Spectrum Pharmaceuticals; Symphogen; Taiho Pharmaceutical; Warp Drive Bio; Zikani Therapeutics
Research Funding - Asana Biosciences; AstraZeneca; Lilly; Sanofi
 
Aparna Raj Parikh
Stock and Other Ownership Interests - C2i genomics
Consulting or Advisory Role - Biofidelity; Checkmate Pharmaceuticals; Guardant Health; Inivata; Lilly; Natera; Pfizer; Roche/Genentech
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Plexxikon (Inst); PMV Pharma; PureTech (Inst)